Pharmacists who understand the workflow before July 1 will be the ones patients and prescribers depend on when the program launches.
I have had this conversation more times than I can count. A patient on Medicare comes to the counter with a prescription for semaglutide (Wegovy; Novo Nordisk) or tirzepatide (Zepbound; Eli Lilly and Company). They have heard about these medications from their physician, from the news, or from a neighbor who lost 40 lb on one of them. They are hopeful. And then I must tell them that Medicare does not cover it for weight loss and that, without coverage, they are looking at $500 or more every month.
The reaction is always the same. Disappointment, then resignation. Some asked if there was anything else they could do. Most just nod and walk away without the prescription. I’ve watched that happen repeatedly for years, which is why July 1, 2026, matters.
That is when the Centers for Medicare & Medicaid Services (CMS) will launch the Medicare glucagon-like peptide-1 (GLP-1) Bridge, a nationwide demonstration program that will provide eligible Medicare Part D beneficiaries with access to select GLP-1 weight-loss medications for a flat $50 monthly co-pay.1 For pharmacists who have had these conversations, who have watched patients weigh their medication costs against their fixed incomes, this is a meaningful shift.
But here is where the excitement and the operational reality need to be separated. The Bridge is not simply an extension of standard Part D coverage with a lower co-pay. It is a fundamentally different claims pathway, and pharmacy teams that do not understand it before July 1 are going to have a difficult first week.
On May 6, 2026, CMS released the full details of the Medicare GLP-1 Bridge, confirming a July 1, 2026, launch date and an end date of December 31, 2027.1 The program is a short-term demonstration established under Section 402 demonstration authority, designed to serve as a bridge to the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) program, which launches for Medicare Part D plan sponsors in January 2027.2
The medications covered under the Bridge are Wegovy in both injectable and tablet formulations, Zepbound in the KwikPen formulation only, and Foundayo (Eli Lilly and Company) in all formulations.3 The Zepbound single-dose vial and single-dose pen formulations are not eligible. Ozempic, Mounjaro, and other GLP-1s prescribed for type 2 diabetes, cardiovascular risk reduction, or sleep apnea remain under standard Part D coverage and are not part of the Bridge.3
So far, so good. But here is where the program gets more complicated than the headlines suggest.
This is the single most important point, and it is the one I expect to be explaining at the counter every day after July 1: The Bridge does not run through the patient's Part D plan or their pharmacy benefit manager. It operates entirely outside the standard Medicare Part D benefit. CMS has established a central processor that handles all prior authorizations, claims adjudication, and pharmacy payments for Bridge prescriptions.2 Part D sponsors are not involved. They did not have to opt in, and they bear no financial risk for Bridge claims.
It does not mean the patient's coverage has changed. Patients who are already receiving a GLP-1 through their Part D plan for a covered indication—type 2 diabetes, cardiovascular risk reduction, or sleep apnea—will remain on their Part D coverage. They are not eligible for the Bridge, and their workflow does not change.2
I want to emphasize this because it will be a source of confusion: the Bridge is not a Part D benefit. It is a parallel federal program with its own authorization process, its own claims system, and its own payment structure.
Processing a Bridge claim the same way you would process a standard Part D claim will result in a rejection.
Eligibility for the Bridge is based on the clinical criteria that were present when the patient first started GLP-1 therapy, not at the time of the Bridge claim.4 This is a nuance worth understanding clearly.
If a patient began a GLP-1 in 2024 with a body mass index (BMI) of 37 and has since lost weight to a BMI of 31, they may still qualify as long as their prescriber can attest that the BMI threshold was met at initiation.4 The prescriber attestation carries the eligibility determination.
To qualify, patients must be enrolled in a standalone Medicare Part D prescription drug plan or a Medicare Advantage plan that includes drug coverage.2 Clinical criteria require a BMI of 35 or higher, or a BMI of 30 or higher combined with at least 1 qualifying condition (heart failure with preserved ejection fraction, uncontrolled hypertension despite treatment, chronic kidney disease, prediabetes, or a history of cardiovascular disease).4 Patients enrolled in private fee-for-service plans, Programs of All-Inclusive Care for the Elderly organizations, or fallback plans are not eligible to participate.2
CMS has established a dedicated Bank Identification Number (BIN 028918) and Processor Control Number (PCN MEDDGLP1BR) specifically for Bridge claims.3 When a patient presents an eligible Bridge prescription, the claim routes to the central processor using this BIN and PCN—not to the patient's Part D plan. Post this at every workstation before July 1. A claim submitted to the wrong processor will be rejected, and the patient standing at the counter will not know why.
Prior authorizations for Bridge prescriptions go to the central processor, not to the Part D plan.2 This is a new workflow for most prescribers, and many offices will be unfamiliar with it. Expect to guide providers through the process in the early weeks as pharmacists routinely do whenever a new payer or program rolls out.
The $50 co-pay does not count toward the patient's Part D out-of-pocket maximum. Because the Bridge sits outside standard Part D, the co-pay is separate from the patient's $2100 annual out-of-pocket cap in 2026.5 Pharmacies collect the $50 directly from the beneficiary, and the central processor reimburses the pharmacy at no less than wholesale acquisition cost, minus the co-pay, plus a dispensing fee and applicable sales tax.3 Pharmacies do not need to opt in. All pharmacies automatically participate.3
Here is the part that will catch people off guard, and it matters for some of the most vulnerable patients on your list. For patients enrolled in the Low-Income Subsidy (LIS) program, the LIS cost-sharing subsidies do not apply to Bridge claims.5 That means a patient who normally pays a few dollars or nothing for their medications under LIS will pay the full $50 Bridge co-pay. For some of these patients, the Bridge co-pay may be higher than what they would pay under their standard plan cost-sharing.
Before a patient in the LIS program fills a Bridge prescription, compare their standard plan cost-sharing for the medication against the $50 Bridge co-pay. If their plan does not cover the drug for weight loss—which most do not—the Bridge may still be the better option. But if there is any existing coverage pathway, the math needs to be checked first.
The Bridge is temporary by design. It is meant to generate real-world utilization data ahead of the BALANCE Model, which is intended to be the durable long-term pathway for GLP-1 access in Medicare.2 Whether that program takes root will depend on political forces that are still very much in motion. A recent analysis found that the longer-term program would cost insurance companies billions in the first year, which has created uncertainty about its future.6
Mohammed Chammout, PharmD, is a practicing pharmacist with more than 5 years of clinical experience in Dearborn, Michigan. His practice focus includes GLP-1 therapeutics, specialty pharmacy access, and prior authorization. He writes about practical pharmacology and patient access issues for Pharmacy Times.
What is not uncertain is the immediate effect on the patients described at the beginning of this article. The ones who heard the price, nodded, and walked away. They are going to come back to the pharmacy counter in July with a different kind of hope, and they are going to need pharmacists who know this program.
When a Bridge claim is rejected because the prescriber submitted the prior authorization to the wrong processor, the pharmacist is the one explaining what happened. When a patient in the LIS program realizes their co-pay is higher than expected, the pharmacist is the one doing the comparison in real time. When a patient asks whether their Zepbound single-dose pen is covered, the pharmacist is the one who knows it is not.
The Medicare GLP-1 Bridge is the most significant expansion of obesity drug access for Medicare patients in the program's history. Pharmacists who understand the workflow before July 1 will be the ones patients and prescribers depend on when it launches. For patients who stop by the pharmacy counter, for the first time in a long time, the answer might actually be yes.
